5. Robert Parkinson - Baxter International

2014 pay: $15.3 million
2015 pay: $17.8 million

Robert Parkinson had a lot on his plate during his last year as Baxter’s ($BAX) CEO in 2015. The med tech helmsman oversaw a spinout of the company’s biopharma business, Baxalta, before former Covidien CEO Jose Almeida took the reins in 2016.

In January 2015, Parkinson said that it would be a “challenging year” for Baxter. But the company is “excited about our future prospects and we’re poised for improved performance in 2016 and beyond,” he said at the time.

After the Baxalta spinout, Baxter wanted to focus on the dialyzer business it bought from Gambro in September 2013 for $4 billion. The company has already said that it would invest $600 million to expand production capacity to meet dialyzer demand.

In October 2015, Baxter revealed that Parkinson would retire as CEO and that Jose Almeida would step in as the company’s new CEO.  “What Joe brings to Baxter in skill and experience is imperative to the company’s stated goal of accelerating profitable growth over the near and long term,” Parkinson said at the time.

During his final year at Baxter, Parkinson took home $17.8 million in pay, including a $1.5 million base salary, $6.5 million in stock awards, $4.8 million in options and $3.6 million in non-equity incentives.

- here’s Baxter International’s proxy statement

For more:
Baxter edges closer to mid-2015 split into separate biopharma, medical product companies
At Baxter, Covidien's Almeida looks to cut costs, fuel innovation and do smaller acquisitions
Baxter makes nice with activist investor Third Point, offers board seats

5. Robert Parkinson - Baxter International

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Daré Bioscience added a microchip-based implant to its pipeline and reported data from a pre-pivotal study of a hormone-free contraceptive ring.